Individual results may vary based on several factors, including severity of disease, initiation of treatment and duration of therapy.*

*Pivotal trials did not include adult patients with spinal muscular atrophy (SMA).

In a SPINRAZA® (nusinersen) pivotal trial, people with later-onset SMA showed meaningful improvements in overall motor functions as measured by Hammersmith Functional Motor Scale–Expanded (HFMSE) compared to placebo at 15 months. Additionally, in a pivotal trial in people with early-onset SMA, a majority of infants were motor milestone responders at 13 months.

Learn more about clinical and real-world trial data

EXPLORE THE DATA

Patients and caregivers are paid spokespersons for Biogen

SPINRAZA may offer improvements for important motor milestones

Maya, age 15 in photo, sitting in a power chair. Has SMA and has been treated with SPINRAZA for 6+years.

Watch some of their stories

Kirra, age 5 in photo, roller skating. Treated with SPINRAZA for 6+ years and before SMA symptoms started.

Discover the data across age groups

Nina, age 39 in photo, has SMA and is pictured looking in a mirror. Aspiring comedian treated with SPINRAZA for 5+ years.

SEE HERE FOR MORE INFORMATION

Over a decade

The safety and efficacy of
SPINRAZA was evaluated in the
longest clinical
trial program in
SMA to date.

3x/year

SPINRAZA is delivered directly to the
cerebrospinal fluid (CSF), the area
surrounding the spinal cord, allowing
it to be distributed to the target
tissues.

Extensive real-world experience across a broad range of ages^†

have been treated with
SPINRAZA worldwide

there’s someone from almost every
age group who has taken
SPINRAZA

have been treated with
SPINRAZA

^†Based on commercial patients and early access patients receiving treatment with SPINRAZA worldwide as of June 2024.

^‡Based on patients receiving treatment with SPINRAZA in the US as of May 2024.

^§SPINRAZA (12 mg) clinical studies included patients from 3 days to 16 years of age at first dose and did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger patients. Pivotal studies did not include adult patients.

SPINRAZA may offer improvements for important motor milestones

Extensive real-world experience across a broad range of ages^†

WHAT IS SPINRAZA?

IMPORTANT SAFETY INFORMATION

SPINRAZA may offer improvements for important motor milestones

Extensive real-world experience across a broad range of ages†

Extensive real-world experience across a broad range of ages^†